8.36

0.60% 0.05

Pre-market: 8.31 -0.05 -0.60%

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $8.36, with a volume of 729.38K. It is up +0.60% in the last 24 hours and up +51.45% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Previous Close:

$8.31

Open:

$8.24

24h Volume:

729.38K

Relative Volume:

0.34

Market Cap:

$510.54M

Revenue:

Net Income/Loss:

$-130.41M

P/E Ratio:

-3.2529

EPS:

-2.57

Net Cash Flow:

$-67.76M

1W Performance:

-3.13%

1M Performance:

+51.45%

6M Performance:

+68.89%

1Y Performance:

+157.23%

1-Day Range:

$8.05

$8.62

1-Week Range:

$7.40

$8.915

52-Week Range:

$2.9106

$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

103

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE	8.36	510.54M	0	-130.41M	-67.76M	-2.57
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

Nov 20, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN

Nov 20, 2024

Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024

Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024

Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024

Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024